13 patents
Utility
Solid forms of a dual RAF/MEK inhibitor
16 Jan 24
Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein.
Farzaneh Seyedi
Filed: 29 Dec 22
Utility
Therapeutic Compositions, Combinations, and Methods of Use
4 Jan 24
This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
Filed: 21 Dec 22
Utility
Solid Forms of a Dual Raf/mek Inhibitor
7 Dec 23
Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein.
Farzaneh Seyedi
Filed: 29 Dec 22
Utility
Combination Therapy for Treating Abnormal Cell Growth
19 Oct 23
The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).
Silvia COMA, Jonathan A. PACHTER
Filed: 13 Jul 21
Utility
Methods and Compositions for Treating Abnormal Cell Growth
12 Oct 23
The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
Jonathan A. Pachter, Winnie Tam, Qunli Xu
Filed: 17 Nov 22
Utility
Methods of Treating Abnormal Cell Growth
29 Jun 23
The present invention relates to methods for treating abnormal cell growth (e.g., cancer) in a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent.
Jonathan A. PACHTER, Daniel PATERSON, Brian M. STUGLIK
Filed: 27 Apr 21
Utility
Compositions and Methods for Treatment of Abnormal Cell Growth
6 Apr 23
This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Mahesh Padval, Paul Okwabi Nkansah
Filed: 10 Jun 22
Utility
Combination Therapy for Treating Abnormal Cell Growth
30 Mar 23
The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
Jonathan A. PACHTER, Silvia COMA
Filed: 28 Jan 21
Utility
Therapeutic compositions, combinations, and methods of use
31 Jan 23
This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
Filed: 25 Nov 19
Utility
Therapeutic Compositions, Combinations, and Methods of Use
21 Oct 20
This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
Filed: 24 Nov 19
Utility
Methods and Compositions for Treating Abnormal Cell Growth
13 May 20
The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).
Jonathan A. Pachter, Winnie Tam, Qunli Xu
Filed: 22 Jul 19
Utility
Compositions and Methods for Treatment of Abnormal Cell Growth
5 Feb 20
This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Mahesh Padval, Paul Okwabi Nkansah
Filed: 10 Mar 19
Utility
Therapeutic compositions, combinations, and methods of use
13 Jan 20
This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
Filed: 28 Jun 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first